(Q36020654)

11 August 2017

1 reference

title

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms (English)

1 reference

11 August 2017

1 reference

Scheen AJ

1

1 reference

11 August 2017

publication date

1 December 2004

1 reference

11 August 2017

published in

Diabetes and Metabolism

1 reference

11 August 2017

volume

30

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

498-505

1 reference

Antihypertensive therapy and incidence of type 2 diabetes: a systematic review

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Pathophysiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The prevention or delay of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Physiology and pathophysiology of the adipose tissue renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Clinical review 79: Angiotensin II: an insulin-sensitizing vasoactive hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and facts

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The hemodynamic link between insulin resistance and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Quinapril treatment enhances vascular sensitivity to insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Pathophysiological implications of insulin resistance on vascular endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Potentiation of Bradykinin Actions by ACE Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Potential role of bradykinin in forearm muscle metabolism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Role of the B(2) receptor of bradykinin in insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Circulating catecholamines and metabolic effects of captopril in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Magnesium and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Cross-talk between the insulin and angiotensin signaling systems

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Crosstalk between insulin and angiotensin II signalling systems

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Adiponectin: more than just another fat cell hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

PPAR(gamma) and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Hypertension, the Potassium Ion and Impaired Carbohydrate Tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effect of experimental potassium deficiency on glucose and insulin metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Pathophysiology of insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Angiotensin II Affects Basal, Pulsatile, and Glucose-Stimulated Insulin Secretion in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970147-7

7 January 2021

10.1016/S1262-3636(07)70147-7

Identifiers

DOI

1 reference

11 August 2017

1 reference